Pharma Capital

Genedrive to present data for its Hepatitis-C test at International Liver Conference

Data will be presented to a host of industry professionals at the event in Amsterdam
Genedrive's HCV ID Kit
The conference is taking place between 19-23 April

Genedrive PLC (LON:GDR) is to showcase data for its rapid diagnostic device for Hepatitis-C (HCV) to industry professionals at the International Liver Conference in Amsterdam later this month.

The clinical validation data for the Genedrive HCV ID Kit will be presented at the conference by Dr Darragh Duffy from the Institut Pasteur in Paris, one of the world’s leading research centres.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

The trials revealed the technology was highly accurate and performed well against the best-in-class device.

Get the best of Proactive delivered straight to your inbox by singing up for our newsletter

“The Genedrive HCV assay will allow decentralised laboratories to provide affordable onsite molecular testing for HCV that aligns with recent WHO testing guidelines," said chief executive David Budd.

“With the wider availability of generic direct acting antiviral agents, the drive in resource limited countries is to cost effectively identify and treat individuals with Hepatitis C.

“We believe that with the performance achieved by the Genedrive HCV assay, there is an opportunity to play a very meaningful role in this strategy.”

CE certification in the works

The molecular diagnostics firm recently submitted the HCV ID Kit for certification under the EU Medical Devices Directive, the receipt of which would green-light the commercialisation of the product in the EU.

Shares opened almost 3% higher at 43.7p on Tuesday.

View full GDR profile

Genedrive PLC Timeline

View All

Related Articles

picture of drug research
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.